AstraZeneca News

AstraZeneca | 6-K: Results of Annual General Meeting Held on 11 April 2024

Apr 11 13:25 ET

AstraZeneca | 6-K: AstraZeneca Increases 2024 Dividend by 7%

Apr 11 06:59 ET

AstraZeneca | 6-K: Enhertu Approved in the US as First Tumour-agnostic HER2-directed Therapy for Previously Treated Patients with Metastatic HER2-positive solid Tumours

Apr 8 06:17 ET

AstraZeneca | 6-K: Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Apr 5 06:27 ET

AstraZeneca | 6-K: Total Voting Rights

Apr 2 13:25 ET

AstraZeneca | 6-K: Voydeya Approved in the Us as Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Haemolysis in Adults with the Rare Disease PNH

Apr 2 08:49 ET

AstraZeneca | 6-K: Datopotamab Deruxtecan Biologics License Application Accepted in the Us for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer

Apr 2 07:59 ET

AstraZeneca | 6-K: Ultomiris Approved in the Us for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

Mar 25 07:33 ET

AstraZeneca | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

Mar 19 17:34 ET

AstraZeneca | 6-K: Astrazeneca to Acquire Fusion to Accelerate the Development of Next-Generation Radioconjugates to Treat Cancer

Mar 19 06:06 ET

AstraZeneca | 6-K: AstraZeneca to Acquire Amolyt

Mar 14 07:14 ET

AstraZeneca | 6-K: Transaction by Person Discharging Managerial Responsibilities

Mar 12 07:32 ET

AstraZeneca | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 7 06:39 ET

AstraZeneca | 6-K: Notice of Annual General Meeting

Mar 7 06:34 ET

AstraZeneca | 6-K: Astrazeneca Plc Announced That, On 5 March 2024, An Award of the Company's Ordinary Shares of $0.25 Each Vested to Pascal Soriot, Executive Director and Chief Executive Officer, Under the Terms of the Astrazeneca Deferred Bonus Plan

Mar 6 10:13 ET

AstraZeneca | 6-K: Transactions by Persons Discharging Managerial Responsibilities

Mar 6 10:08 ET

AstraZeneca | 6-K: EMA validates Dato-DXd MAAs for NSQ NSCLC and BC

Mar 4 06:35 ET

AstraZeneca | 6-K: Voting Rights and Capital

Mar 1 10:44 ET

AstraZeneca | 6-K: Voydeya Recommended for Approval in the Eu by CHMP as Add-On Treatment to Ravulizumab or Eculizumab for Adults with PNH Who Have Residual Haemolytic Anaemia

Feb 26 06:25 ET

AstraZeneca | 6-K: Astrazeneca Prices a $5bn Bond Offering

Feb 22 09:21 ET